Related Experiment Video
Updated: Feb 13, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia
Stefano Baldoni1, Beatrice Del Papa2, Erica Dorillo2
1Hematology Section, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
Abstract:
Dysregulated NOTCH1 signaling, by either gene mutations or microenvironment interactions, has been increasingly linked to chronic lymphocytic leukemia (CLL). Thus, inhibiting NOTCH1 activity represents a potential therapeutic opportunity for this disease. Using gene expression-based screening, we identified the calcium channel modulator bepridil as a new NOTCH1 pathway inhibitor. In primary CLL cells, bepridil induced selective apoptosis even in the presence of the protective stroma. Cytotoxic effects of bepridil were independent of NOTCH1 mutation and other prognostic markers. The antitumor efficacy of bepridil was associated with inhibition of NOTCH1 activity through a decrement in trans-membrane and activated NOTCH1 protein levels with unchanged NOTCH2 protein levels. In a CLL xenotransplant model, bepridil significantly reduced the percentage of leukemic cells infiltrating the spleen via enhanced apoptosis and decreased NOTCH1 activation. In conclusion, we report in vitro and in vivo anti-leukemic activity of bepridil associated with inhibition of the NOTCH1 pathway in CLL. These data provide a rationale for the clinical development of bepridil as anti-NOTCH1 targeted therapy for CLL patients.
Insights
The calcium channel modulator bepridil effectively targets NOTCH1 signaling in chronic lymphocytic leukemia (CLL) cells, inducing apoptosis and reducing leukemic cell infiltration in preclinical models.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- NOTCH1 signaling pathway dysregulation is implicated in chronic lymphocytic leukemia (CLL) pathogenesis.
- Targeting NOTCH1 offers a potential therapeutic strategy for CLL.
Purpose of the Study:
- To identify novel inhibitors of the NOTCH1 pathway for CLL treatment.
- To evaluate the anti-leukemic activity of bepridil in CLL.
Main Methods:
- Gene expression-based screening to identify NOTCH1 pathway inhibitors.
- In vitro studies using primary CLL cells and co-culture systems with protective stroma.
- In vivo evaluation in a CLL xenotransplant mouse model.
Main Results:
- Bepridil was identified as a novel NOTCH1 pathway inhibitor.
- Bepridil induced selective apoptosis in primary CLL cells, irrespective of NOTCH1 mutation status.
- Bepridil reduced NOTCH1 activity by decreasing transmembrane and activated NOTCH1 protein levels.
- In vivo studies demonstrated bepridil's efficacy in reducing leukemic cell infiltration and NOTCH1 activation.
Conclusions:
- Bepridil exhibits in vitro and in vivo anti-leukemic activity in CLL by inhibiting the NOTCH1 pathway.
- These findings support the clinical development of bepridil as a targeted therapy for CLL.
More Related Videos
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Related Concept Videos
Inhibition of Cdk Activity
Feedback Inhibition
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Enzyme Inhibition
Other Glycolytic Pathways
Respiration Pathways